CD163 and COVID-19: Finally, as already reported [58,59,60], we confirmed the increase in plasma levels of sCD163 and sCD14 on the hospital admission of COVID-19 patients, especially in those who developed ARDS, highlighting their potential use when assessing the risk of progression in the disease.